肝癌肿瘤微环境与消融治疗的研究现状与展望

doi:10.3760/cma.j.cn371439-20240328-00110

摘要/Abstract

摘要：

肝癌是常见的恶性肿瘤之一，大多数患者就诊时已处于中晚期。消融治疗是早期肝癌或无法手术切除肝癌患者主要的治疗方法。肿瘤微环境的变化可能会对肝癌消融术后患者的疗效及预后产生影响。近年来，越来越多的研究探索肝癌消融治疗与肿瘤微环境之间潜在的协同作用，以改善消融治疗疗效并提高生存率。探讨肝癌肿瘤微环境的关键组成部分及肿瘤微环境在肝癌消融治疗中发挥的免疫调节作用，可为肝癌治疗提供新策略。

关键词: 癌，肝细胞, 肿瘤微环境, 介入治疗

Abstract:

Liver cancer is one of the common malignant tumors， and most patients are in the middle and advanced stages when they seek medical attention. Ablation therapy is the main treatment for patients with early or unresectable liver cancer. Changes in the tumor microenvironment may affect the efficacy and prognosis of patients after ablation of liver cancer. In recent years， more and more studies have explored the potential synergistic effect between ablation therapy for liver cancer and the tumor microenvironment to improve the efficacy of ablation therapy and improve survival rate. Exploring the key components of the tumor microenvironment and the immunomodulatory role of the tumor microenvironment in the ablation treatment of liver cancer can provide a new strategy for the treatment of liver cancer.

Key words: Carcinoma， hepatocellular, Tumor microenvironment, Interventional therapy

何佩霈, 杨朝凤, 李杨. 肝癌肿瘤微环境与消融治疗的研究现状与展望[J]. 国际肿瘤学杂志, 2024, 51(10): 655-659.

He Peipei, Yang Chaofeng, Li Yang. Research status and prospect of tumor microenvironment and ablation therapy for liver cancer[J]. Journal of International Oncology, 2024, 51(10): 655-659.

参考文献 41

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]	Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6. DOI: 10.1038/s41572-020-00240-3. pmid: 33479224
[3]	Xie L, Meng Z. Immunomodulatory effect of locoregional therapy in the tumor microenvironment[J]. Mol Ther, 2023, 31(4): 951-969. DOI: 10.1016/j.ymthe.2023.01.017. pmid: 36694462
[4]	田堰鑫, 李娜, 高雷, 等. 肿瘤微环境与肝癌干细胞相互作用对肝细胞癌发生发展的影响[J]. 临床肝胆病杂志, 2023, 39(3): 684-692. DOI: 10.3969/j.issn.1001-5256.2023.03.032.
[5]	汪鹏, 仇建南, 王忠夏, 等. 肝癌微环境中肿瘤相关巨噬细胞的研究进展[J]. 临床肝胆病杂志, 2023, 39(5): 1212-1218. DOI: 10.3969/j.issn.1001-5256.2023.05.033.
[6]	Ezhilarasan D, Najimi M. Deciphering the possible reciprocal loop between hepatic stellate cells and cancer cells in the tumor microenvironment of the liver[J]. Crit Rev Oncol Hematol, 2023, 182: 103902. DOI: 10.1016/j.critrevonc.2022.103902.
[7]	Peng H, Zhu E, Zhang Y. Advances of cancer-associated fibroblasts in liver cancer[J]. Biomark Res, 2022, 10(1): 59. DOI: 10.1186/s40364-022-00406-z. pmid: 35971182
[8]	He X, Huang ZZ, Liu P, et al. Apatinib inhibits the invasion and metastasis of liver cancer cells by downregulating MMP-related proteins via regulation of the NF- κ B signaling pathway[J]. Biomed Res Int, 2020, 2020: 3126182. DOI: 10.1155/2020/3126182.
[9]	田津铭, 杨继金. 局部介入联合免疫检查点抑制剂治疗中晚期肝癌研究进展[J]. 国际肿瘤学杂志, 2023, 50(10): 636-640. DOI: 10.3760/cma.j.cn371439-20230428-00121.
[10]	马千, 常乐乐, 陶冀. 免疫治疗与消融治疗在肝细胞癌中的研究进展与现状[J]. 肿瘤研究与临床, 2023, 35(12): 947-950. DOI: 10.3760/cma.j.cn115355-20221214-00789.
[11]	Wu J, Chan Y, Lu Y, et al. The tumor microenvironment in the postsurgical liver: mechanisms and potential targets of postoperative recurrence in human hepatocellular carcinoma[J]. Med Res Rev, 2023, 43(6): 1946-1973. DOI: 10.1002/med.21967.
[12]	Ridouani F, Srimathveeravalli G. Percutaneous image-guided ablation: from techniques to treatments[J]. Presse Med, 2019, 48(7/8 Pt 2): e219-e231. DOI: 10.1016/j.lpm.2019.06.005.
[13]	Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma[J]. Hepatology, 2023, 78(6): 1922-1965. DOI: 10.1097/HEP.0000000000000466. pmid: 37199193
[14]	European Association for the Study of the Liver, Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019.
[15]	Zeng X, Liao G, Li S, et al. Eliminating METTL1-mediated accumulation of PMN-MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation[J]. Hepatology, 2023, 77(4): 1122-1138. DOI: 10.1002/hep.32585.
[16]	Tian Z, Hu Q, Sun Z, et al. A booster for radiofrequency ablation: advanced adjuvant therapy via in situ nanovaccine synergized with anti-programmed death ligand 1 immunotherapy for systemically constraining hepatocellular carcinoma[J]. ACS Nano, 2023, 17(19): 19441-19458. DOI: 10.1021/acsnano.3c08064.
[17]	Zhao Y, Yang T, Ouyang Y, et al. Radiofrequency ablation plays double role in immunosuppression and activation of PBMCs in recurrent hepatocellular carcinoma[J]. Front Immunol, 2024, 15: 1339213. DOI: 10.3389/fimmu.2024.1339213.
[18]	Yang J, Yan J, Liu B. Targeting VEGF/VEGFR to modulate antitumor immunity[J]. Front Immunol, 2018, 9: 978. DOI: 10.3389/fimmu.2018.00978. pmid: 29774034
[19]	Yang D, Zhuang B, Wang Y, et al. Radiofrequency ablation versus hepatic resection for recurrent hepatocellular carcinoma: an updated meta-analysis[J]. BMC Gastroenterol, 2020, 20(1): 402. DOI: 10.1186/s12876-020-01544-0. pmid: 33246417
[20]	Qi X, Yang M, Ma L, et al. Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response[J]. J Immunother Cancer, 2020, 8(2): e001038. DOI: 10.1136/jitc-2020-001038.
[21]	Shi L, Wang J, Ding N, et al. Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy[J]. Nat Commun, 2019, 10(1): 5421. DOI: 10.1038/s41467-019-13204-3. pmid: 31780645
[22]	Chen S, Zeng X, Su T, et al. Combinatory local ablation and immunotherapies for hepatocellular carcinoma: rationale, efficacy, and perspective[J]. Front Immunol, 2022: 1033000. DOI: 10.3389/fimmu.2022.1033000.
[23]	Duan X, Wang M, Han X, et al. Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice[J]. Cell Cycle, 2020, 19(24): 3595-3607. DOI: 10.1080/15384101.2020.1853942. pmid: 33283623
[24]	中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J]. 中国普通外科杂志, 2024, 23(3): 475-530. DOI: 10.7659/j.issn.1005-6947.2024.04.001.
[25]	刘宜翔, 牛坚, 王梦, 等. 外周血白细胞介素-27及临床病理因素对肝癌微波消融后发生局部肿瘤进展的预测价值[J]. 国际外科学杂志, 2020, 47(2): 92-97. DOI: 10.3760/cma.j.issn.1673-4203.2020.02.005.
[26]	Zhou Y, Xu X, Ding J, et al. Dynamic changes of T-cell subsets and their relation with tumor recurrence after microwave ablation in patients with hepatocellular carcinoma[J]. J Cancer Res Ther, 2018, 14(1): 40-45. DOI: 10.4103/jcrt.JCRT_775_17. pmid: 29516957
[27]	Chen Y, Bei J, Chen M, et al. Intratumoral lactate depletion based on injectable nanoparticles-hydrogel composite system synergizes with immunotherapy against postablative hepatocellular carcinoma recurrence[J]. Adv Healthc Mater, 2024, 13(6): e2303031. DOI: 10.1002/adhm.202303031.
[28]	Cui R, Wang L, Zhang DY, et al. Combination therapy using microwave ablation and D-mannose-chelated iron oxide nanoparticles inhibits hepatocellular carcinoma progression[J]. Acta Pharm Sin B, 2022, 12(9): 3475-3485. DOI: 10.1016/j.apsb.2022.05.026. pmid: 36176908
[29]	程小育. 调控肿瘤微环境的智能型纳米药物增敏肝癌微波消融治疗的基础研究[D]. 郑州: 郑州大学, 2022. DOI: 10.27466/d.cnki.gzzdu.2022.002830.
[30]	宋振宇, 史瑶平, 翟博. 冷冻消融术治疗肝癌的研究进展[J/OL]. 肿瘤, 2023: 1-7. (2023-09-01) DOI: 10.3781/j.issn.1000-7431.2023.2307-0363.
[31]	Kwak K, Yu B, Lewandowski RJ, et al. Recent progress in cryoablation cancer therapy and nanoparticles mediated cryoablation[J]. Theranostics, 2022, 12(5): 2175-2204. DOI: 10.7150/thno.67530. pmid: 35265206
[32]	Lin M, Liang S, Wang X, et al. Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer[J]. Oncotarget, 2017, 8(47): 81967-81977. DOI: 10.18632/oncotarget.17804. pmid: 29137237
[33]	Shewarega A, Santana JG, Nam D, et al. Effect of incomplete cryoablation and matrix metalloproteinase inhibition on intratumoral CD8⁺ T-cell infiltration in murine hepatocellular carcinoma[J]. Radiology, 2024, 310(2): e232365. DOI: 10.1148/radiol.232365.
[34]	魏颖恬, 肖越勇, 王忠敏. 影像学引导下不可逆电穿孔消融治疗肝脏恶性肿瘤专家共识(2022版)[J]. 中国介入影像与治疗学, 2022, 19(5): 257-262. DOI: 10.13929/j.issn.1672-8475.2022.05.001.
[35]	Dai Z, Wang Z, Lei K, et al. Irreversible electroporation induces CD8⁺ T cell immune response against post-ablation hepatocellular carcinoma growth[J]. Cancer Lett, 2021, 503: 1-10. DOI: 10.1016/j.canlet.2021.01.001.
[36]	Sugimoto K, Kakimi K, Takeuchi H, et al. Irreversible electroporation versus radiofrequency ablation: comparison of systemic immune responses in patients with hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2019, 30(6): 845-853.e6. DOI: 10.1016/j.jvir.2019.03.002. pmid: 31126596
[37]	Yang Y, Qin Z, Du D, et al. Safety and short-term efficacy of irreversible electroporation and allogenic natural killer cell immunotherapy combination in the treatment of patients with unresectable primary liver cancer[J]. Cardiovasc Intervent Radiol, 2019, 42(1): 48-59. DOI: 10.1007/s00270-018-2069-y. pmid: 30151798
[38]	侯思楠, 王卫东, 钟泽龙, 等. 不可逆电穿孔消融术联合PD-1抑制剂治疗小鼠肝癌效果初步研究[J]. 介入放射学杂志, 2019, 28(5): 454-458. DOI: 10.3969/j.issn.1008-794X.2019.05.011.
[39]	陈诚, 王俊杰, 吴涯昆. 高强度聚焦超声在中晚期肝癌中的临床应用进展[J]. 肝胆胰外科杂志, 2021, 33(12): 765-768, 775. DOI: 10.11952/j.issn.1007-1954.2021.12.014.
[40]	Ran LF, Xie XP, Xia JZ, et al. T-lymphocytes from focused ultrasound ablation subsequently mediate cellular antitumor immunity after adoptive cell transfer immunotherapy[J]. Front Immunol, 2023, 14: 1155229. DOI: 10.3389/fimmu.2023.1155229.
[41]	叶合敏, 黄楠, 孙廷宇, 等. 金属有机纳米粒的制备及其在高强度聚焦超声治疗小鼠肝癌中的增效作用[J]. 南方医科大学学报, 2021, 41(5): 640-648. DOI: 10.12122/j.issn.1673-4254.2021.05.02.